Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY
NCT06683755Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Aug 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, relatlimab and ipilimumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events, Recommended Phase IIa Dose and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06683755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683755.